The clinical epidemiology of male osteoporosis: A review of the recent literature

Clinical Epidemiology

Volumn 7, Issue , 2015, Pages 65-76

  Willson, Tina ^a,b   Nelson, Scott D ^a,b   Newbold, Jonathan ^a   Nelson, Richard E ^b,c   LaFleur, Joanne ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnosis; Fracture risk; Guidelines; Screening; Treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; PARATHYROID HORMONE[1-34]; VITAMIN D;

BONE DENSITY; BONE DEVELOPMENT; CLINICAL EFFECTIVENESS; DIAGNOSTIC TEST; DISEASE COURSE; EVIDENCE BASED MEDICINE; FRAGILITY FRACTURE; HUMAN; INCIDENCE; MALE; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; PUBLIC HEALTH PROBLEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; VITAMIN SUPPLEMENTATION; WORLD HEALTH ORGANIZATION;

EID: 84921278969     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S40966     Document Type: Review

References (97)

1. Becker DJ, Kilgore ML, Morrisey MA. The societal burden of osteoporosis. Curr Rheumatol Rep. 2010;12(3):186-191.
2. National Osteoporosis Foundation [webpage on the Internet]. Just for Men. Available at: http://nof.org/articles/236. Accessed September 30, 2013.
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726-1733.
4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-475.
5. von Friesendorff M, McGuigan FE, Besjakov J, Akesson K. Hip fracture in men-survival and subsequent fractures: a cohort study with 22-year follow-up. J Am Geriatr Soc. 2011;59(5):806-813.
6. Bonjour JP, Theintz G, Law F, Slosman D, Rizzoli R. Peak bone mass. Osteoporos Int. 1994;4 Suppl 1:7-13.
7. Lambert JK, Zaidi M, Mechanick JI. Male osteoporosis: epidemiology and the pathogenesis of aging bones. Curr Osteoporos Rep. 2011;9(4): 229-236.
8. Seeman E. Growth in bone mass and size - are racial and gender differences in bone mineral density more apparent than real? J Clin Endocrinol Metab. 1998;83(5):1414-1419.
9. Karsenty G. The mutual dependence between bone and gonads. J Endocrinol. 2012;213(2):107-114.
10. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23(3):279-302.
11. De Oliveira DH, Fighera TM, Bianchet LC, Kulak CA, Kulak J. Androgens and bone. Minerva Endocrinol. 2012;37(4):305-314.
12. Looker AC, Beck TJ, Orwoll ES. Does body size account for gender differences in femur bone density and geometry? J Bone Miner Res. 2001;16(7):1291-1299.
13. Vandewalle S, Taes Y, Van Helvoirt M, et al. Bone size and bone strength are increased in obese male adolescents. J Clin Endocrinol Metab. 2013;98(7):3019-3028.
14. Heidemann M, Mølgaard C, Husby S, et al. The intensity of physical activity influences bone mineral accrual in childhood: the childhood health, activity and motor performance school (the CHAMPS) study, Denmark. BMC Pediatr. 2013;13:32.
15. Duan Y, Beck TJ, Wang XF, Seeman E. Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging. J Bone Miner Res. 2003;18(10):1766-1774.
16. Seeman E. The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinol Metab Clin North Am. 2003;32(1):25-38.
17. Gennari L, Bilezikian JP. Idiopathic osteoporosis in men. Curr Osteoporos Rep. 2013;11(4):286-298.
18. Gennari L, Brandi ML. Genetics of male osteoporosis. Calcif Tissue Int. 2001;69(4):200-204.
19. Cohen-Solal ME, Baudoin C, Omouri M, Kuntz D, De Vernejoul MC. Bone mass in middle-aged osteoporotic men and their relatives: familial effect. J Bone Miner Res. 1998;13(12):1909-1914.
20. Van Pottelbergh I, Goemaere S, Zmierczak H, De Bacquer D, Kaufman JM. Deficient acquisition of bone during maturation underlies idiopathic osteoporosis in men: evidence from a three-generation family study. J Bone Miner Res. 2003;18(2):303-311.
21. Silva DR, Coelho AC, Dumke A, et al. Osteoporosis prevalence and associated factors in patients with COPD: a cross-sectional study. Respir Care. 2011;56(7):961-968.
22. Morden NE, Sullivan SD, Bartle B, Lee TA. Skeletal health in men with chronic lung disease: rates of testing, treatment, and fractures. Osteoporos Int. 2011;22(6):1855-1862.
23. Shen C, Deng J, Zhou R, et al. Relation between bone mineral density, bone loss and the risk of cardiovascular disease in a Chinese cohort. Am J Cardiol. 2012;110(8):1138-1142.
24. Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos Int. 2011;22(2):421-433.
25. Castaño-Betancourt MC, Rivadeneira F, Bierma-Zeinstra S, et al. Bone parameters across different types of hip osteoarthritis and their relationship to osteoporotic fracture risk. Arthritis Rheum. 2013;65(3): 693-700.
26. Hearn AP, Silber E. Osteoporosis in multiple sclerosis. Mult Scler. 2010;16(9):1031-1043.
27. Bazelier MT, de Vries F, Bentzen J, et al. Incidence of fractures in patients with multiple sclerosis: the Danish National Health Registers. Mult Scler. 2012;18(5):622-627.
28. Gennari L, Bilezikian JP. Osteoporosis in men. Endocrinol Metab Clin North Am. 2007;36(2):399-419.
29. Nelson RE, Nebeker JR, Sauer BC, LaFleur J. Factors associated with screening or treatment initiation among male United States veterans at risk for osteoporosis fracture. Bone. 2012;50(4):983-988.
30. Gielen E, Vanderschueren D, Callewaert F, Boonen S. Osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2011;25(2):321-335.
31. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29(4):441-464.
32. Mosekilde L, Vestergaard P, Rejnmark L. The pathogenesis, treatment and prevention of osteoporosis in men. Drugs. 2013;73(1):15-29.
33. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137-1141.
34. Faulkner KG, Orwoll E. Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom. 2002;5(1):87-93.
35. Kanis JA, Bianchi G, Bilezikian JP, et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int. 2011;22(11): 2789-2798.
36. Brunader R, Shelton DK. Radiologic bone assessment in the evaluation of osteoporosis. Am Fam Physician. 2002;65(7):1357-1364.
37. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008;42(3):467-475.
38. Compston J, Bowring C, Cooper A, et al; National Osteoporosis Guideline Group. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013;75(4):392-396.
39. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2014. Available from: http://nof.org/hcp/clinicians-guide. Accessed April 11, 2014.
40. Watts NB, Adler RA, Bilezikian JP, et al; Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(6):1802-1822.
41. Papaioannou A, Morin S, Cheung AM, et al; Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182(17):1864-1873.
42. Watts NB, Leslie WD, Foldes AJ, Miller PD. 2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. J Clin Densitom. 2013;16(4):472-481.
43. Blume SW, Curtis JR. Medical costs of osteoporosis in the elderly Medicare population. Osteoporos Int. 2011;22(6):1835-1844.
44. Frost M, Wraae K, Abrahamsen B, et al. Osteoporosis and vertebral fractures in men aged 60-74 years. Age Ageing. 2012;41(2):171-177.
45. Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1-2):136.
46. Nelson HD, Haney EM, Dana T, Bougatsos C, Chou R. Screening for osteoporosis: an update for the US. Preventive Services Task Force. Ann Intern Med. 2010;153(2):99-111.
47. Kim SH, Meehan JP, Blumenfeld T, Szabo RM. Hip fractures in the United States: 2008 nationwide emergency department sample. Arthritis Care Res (Hoboken). 2012;64(5):751-757.
48. Diamantopoulos AP, Rohde G, Johnsrud I, et al. Incidence rates of fragility hip fracture in middle-aged and elderly men and women in southern Norway. Age Ageing. 2012;41(1):86-92.
49. Bow CH, Cheung E, Cheung CL, et al. Ethnic difference of clinical vertebral fracture risk. Osteoporos Int. 2012;23(3):879-885.
50. Omsland TK, Holvik K, Meyer HE, et al. Hip fractures in Norway 1999-2008: time trends in total incidence and second hip fracture rates: a NOREPOS study. Eur J Epidemiol. 2012;27(10):807-814.
51. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA. 2009;302(14): 1573-1579.
52. Leslie WD, O'Donnell S, Jean S, et al; Osteoporosis Surveillance Expert Working Group. Trends in hip fracture rates in Canada. JAMA. 2009;302(8):883-889.
53. Hiligsmann M, Bruyère O, Roberfroid D, et al. Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000-2007). Arthritis Care Res (Hoboken). 2012;64(5):744-750.
54. Hartholt KA, Oudshoorn C, Zielinski SM, et al. The epidemic of hip fractures: are we on the right track? PLoS One. 2011;6(7):e22227.
55. Oudshoorn C, Hartholt KA, Zillikens MC, et al. Emergency department visits due to vertebral fractures in The Netherlands, 1986-2008: steep increase in the oldest old, strong association with falls. Injury. 2012;43(4):458-461.
56. Chen CW, Huang TL, Su LT, et al. Incidence of subsequent hip fractures is significantly increased within the first month after distal radius fracture in patients older than 60 years. J Trauma Acute Care Surg. 2013;74(1):317-321.
57. Thorstenson A, Bratt O, Akre O, et al. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden. Eur J Cancer. 2012;48(11):1672-1681.
58. Melton LJ 3rd, Lieber MM, Atkinson EJ, et al. Fracture risk in men with prostate cancer: a population-based study. J Bone Miner Res. 2011;26(8):1808-1815.
59. United States Bureau of Labor Statistics [webpage on the Internet]. Consumer Price Index - All Urban Consumers. Available at: http://www.bls.gov/cpi/data.htm. Accessed March 25, 2014.
60. International Monetary Fund [webpage on the Internet]. Exchange Rate Data. Available at: http://www.imf.org/external/data.htm. Accessed March 24, 2014.
61. Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services; 2004.
62. Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US. Pharmacoeconomics. 2010;28(5):395-409.
63. Rousculp MD, Long SR, Wang S, Schoenfeld MJ, Meadows ES. Economic burden of osteoporosis-related fractures in Medicaid. Value Health. 2007;10(2):144-152.
64. Tarride JE, Guo N, Hopkins R, et al. The burden of illness of osteoporosis in Canadian men. J Bone Miner Res. 2012;27(8):1830-1838.
65. Hiligsmann M, Ethgen O, Richy F, Reginster JY. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int. 2008;82(4):288-292.
66. Lewis CE, Ewing SK, Taylor BC, et al; Osteoporotic Fractures in Men (MrOS) Study Research Group. Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res. 2007;22(2):211-219.
67. Drake MT, Murad MH, Mauck KF, et al. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(6):1861-1870.
68. Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone. 2008;43(6):1115-1121.
69. US Preventive Services Task Force. Screening for osteoporosis: US preventive services task force recommendation statement. Ann Intern Med. 2011;154(5):356-364.
70. Schousboe JT, Taylor BC, Fink HA, et al. COst-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA. 2007;298(6):629-637.
71. Malabanan AO, Rosen HN, Vokes TJ, et al. Indications of DXA in women younger than 65 yr and men younger than 70 yr: the 2013 Official Positions. J Clin Densitom. 2013;16(4):467-471.
72. Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34(1):195-202.
73. Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV; Epidemiology and Quality of Life Working Group of IOF. Worldwide uptake of FRAX. Arch Osteoporos. 2014;9(1):166.
74. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int. 2008;19(10):1431-1444.
75. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ. 2012;344:e3427.
76. Sandhu SK, Nguyen ND, Center JR, Pocock NA, Eisman JA, Nguyen TV. Prognosis of fracture: evaluation of predictive accuracy of the FRAX algorithm and Garvan nomogram. Osteoporos Int. 2010;21(5):863-871.
77. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA; Manitoba Bone Density Program. Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res. 2010;25(11):2350-2358.
78. Ettinger B, Ensrud KE, Blackwell T, Curtis JR, Lapidus JA, Orwoll ES; Osteoporotic Fracture in Men (MrOS) Study Research Group. Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int. 2013;24(4):1185-1193.
79. LaFleur J, Nelson RE, Yao Y, Adler RA, Nebeker JR. Validated risk rule using computerized data to identify males at high risk for fracture. Osteoporos Int. 2012;23(3):1017-1027.
80. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515-1526.
81. Olofsson H, Byberg L, Mohsen R, Melhus H, Lithell H, Michaëlsson K. Smoking and the risk of fracture in older men. J Bone Miner Res. 2005;20(7):1208-1215.
82. Felson DT, Kiel DP, Anderson JJ, Kannel WB. Alcohol consumption and hip fractures: the Framingham Study. Am J Epidemiol. 1988;128(5):1102-1110.
83. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293(18):2257-2264.
84. de Kam D, Smulders E, Weerdesteyn V, Smits-Engelsman BC. Exercise interventions to reduce fall-related fractures and their risk factors in individuals with low bone density: a systematic review of randomized controlled trials. Osteoporos Int. 2009;20(12):2111-2125.
85. Herrera A, Lobo-Escolar A, Mateo J, Gil J, Ibarz E, Gracia L. Male osteoporosis: a review. World J Orthop. 2012;3(12):223-234.
86. Schwarz P, Jorgensen NR, Mosekilde L, Vestergaard P. The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men. J Osteoporos. 2011;2011:259818.
87. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148(3):197-213.
88. Murad MH, Drake MT, Mullan RJ, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2012;97(6):1871-1880.
89. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604-610.
90. Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med. 2005;165(15):1743-1748.
91. Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367(18): 1714-1723.
92. Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int. 2009;29(3):311-315.
93. Adler RA. Osteoporosis in men: recent progress. Endocrine. 2013;44(1): 40-46.
94. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16(5):510-516.
95. Orwoll E, Teglbjærg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97(9): 3161-3169.
96. Smith MR, Egerdie B, Hernández Toriz N, et al; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8): 745-755.
97. Kaufman JM, Audran M, Bianchi G, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab. 2013;98(2):592-601.